NCT01498562View on ClinicalTrials.gov

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Gefitinib and Nimotuzumab

Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)

DRUG

Gefitinib

Mono-therapy group: Gefitinib(250mg daily)

Trial Locations (1)

Unknown

Severance hospital, Yonsei Cancer Center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01498562 - Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter